Sage, Biogen now plan to submit depression drug candidate to FDA in second half of 2022Market Watch • 10/20/21
Stocks making the biggest moves before the bell: Biogen, Novavax, Netflix, Verizon & moreCNBC • 10/20/21
Biogen's stock is up on strong earnings; new Alzheimer's drug had $300,000 in sales in Q3Market Watch • 10/20/21
Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & Drug Administration in the Second Half of 2022 with Rolling Submission Expected to Start in Early 2022Business Wire • 10/19/21
Biogen's Antisense Candidate Flunks In Late-Stage Neurodegenerative Disorder TrialBenzinga • 10/18/21
Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALSGlobeNewsWire • 10/17/21
Topline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-ALS to be Presented at the American Neurological Association Annual MeetingGlobeNewsWire • 10/14/21
New Data at ECTRIMS 2021 Highlight Biogen's Focus on Patient-Centered Outcomes and Improving the MS Patient ExperienceGlobeNewsWire • 10/13/21
New MS PATHS Data at ECTRIMS 2021 Confirm Biogen's Disease-Modifying Therapies Do Not Reduce Antibody Response to COVID-19 Vaccines in People with Multiple SclerosisGlobeNewsWire • 10/13/21
Could Biogen's Blockbuster Hopes for Alzheimer's Disease Drug Aduhelm Be Doomed?The Motley Fool • 10/08/21
